Newer drug treatments: their effects on fracture prevention.
Drug treatment of osteoporosis is based on the knowledge of mechanisms of bone turnover and the manipulation of the cellular components of bone turnover in terms of recruitment, activation and apoptosis of the cells involved. Based on their mechanisms of action, drugs used in the treatment of osteoporosis can be divided into those that inhibit bone turnover (bisphosphonates, SERMs, calcitonin), those that stimulate bone turnover (parathyroid hormone), and those with mixed effects (strontium ranelate). In this chapter we discuss the anti-fracture effects of some newer drugs together with innovative aspects of intake (monthly oral intake for ibandronate) or mechanisms of action (parathyroid hormone and strontium ranelate). Some new drugs that are being studied for their potential anti-fracture effects are listed.
Geusens
Piet
P
Biomedical Research Institute, University Hasselt, Campus Diepenbeek, Belgium. piet.geusens@scarlet.be
Reid
David
D
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002116:Calcitonin / Q000627:therapeutic use; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006023:Glycoproteins / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000077557:Ibandronic Acid; D007093:Imidazoles / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D010024:Osteoporosis / Q000150:complications / Q000517:prevention & control*; D053244:Osteoprotegerin; D010281:Parathyroid Hormone / Q000627:therapeutic use; D053245:RANK Ligand; D018160:Receptors, Cytoplasmic and Nuclear / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D000077211:Zoledronic Acid
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D006023:Glycoproteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007093:Imidazoles; D009942:Organometallic Compounds; D053244:Osteoprotegerin; D010281:Parathyroid Hormone; D053245:RANK Ligand; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human; D013876:Thiophenes; C081587:strontium ranelate; D000069448:Denosumab; D000077211:Zoledronic Acid; D002116:Calcitonin; D000077557:Ibandronic Acid